| (Values in U.S. Thousands) | Dec, 2018 | Sep, 2018 | Jun, 2018 | Mar, 2018 | Dec, 2017 |
| Sales | 2,020 | 2,000 | 2,560 | 2,140 | 1,870 |
| Sales Growth | +1.00% | -21.88% | +19.63% | +14.44% | +222.41% |
| Net Income | -47,520 | -41,790 | -49,970 | -47,230 | -36,380 |
| Net Income Growth | -13.71% | +16.37% | -5.80% | -29.82% | -21.63% |
Achaogen Inc (AKAO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Achaogen, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of novel antibacterials to treat multi-drug resistant, or MDR, gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR enterobacteriaceae, including carbapenem-resistant enterobacteriaceae. Achaogen, Inc. is headquartered in South San Francisco, California.